AstraZeneca PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
AstraZeneca PLC Stock Forecast and Price Target
AstraZeneca PLC has an average price target of £164.51 recently offered by four notable experts for 2023, which would represent a potential upside of approximately 66.17% from the last closing price in November, 2023 if reached. This potential increase is based on a high estimate of £212.90 and a low estimate of £135.10. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.
66.17% Upside
AstraZeneca PLC Fair Value Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Price has grown in the last three years, jumping from £60.73 to £115.55 – an increase of 90.29%. In the next year, analysts predict that Fair Value will reach £126.66 – an increase of 9.61%. For the next eight years, the forecast is for Fair Value to grow by 94.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$591.60 | Buy/Sell | $594.01 | 9.87% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr687.90 | Buy/Sell | kr696.07 | 12.30% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$151.63 | Buy/Sell | $176.14 | 13.43% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$100.18 | Buy/Sell | $123.75 | 24.78% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$138.08 | Buy/Sell | $167.35 | 20.94% |
AstraZeneca PLC Revenue Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Revenue has grown in the last three years, jumping from £24.38B to £44.35B – an increase of 81.89%. In the next year, analysts predict that Revenue will reach £45.76B – an increase of 3.17%. For the next eight years, the forecast is for Revenue to grow by 46.60%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Outperform |
9
|
CHF86.00 | Buy/Sell | CHF103.75 | 17.87% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$102.06 | Buy/Sell | $116.25 | 12.97% |
| AMGN Stock Forecast | Amgen Inc | Outperform |
7
|
$265.52 | Buy/Sell | $275.75 | 8.09% |
.jpg)
AstraZeneca PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's Dividend per Share has increased by 3.57%, going from £2.80 to £2.90. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £3.01 – an increase of 3.79%. The AstraZeneca PLC forecast is for Dividend per Share to reach £5.28 or grow by 82.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic PLC | Outperform |
11
|
$78.63 | Buy/Sell | $90.05 | 14.46% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$74.51 | Buy/Sell | $87.30 | 21.46% |
AstraZeneca PLC Free Cash Flow Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Free Cash Flow has increased by 338.04% In the last three years, going from £1.99B to £8.72B. According to 2 analysts, AstraZeneca PLC's Free Cash Flow will fall by 33.17% in the next year, reaching £5.83B. For the next eight years, the forecast is for Free Cash Flow to grow by 169.81%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Buy |
12
|
$256.88 | Buy/Sell | $207.22 | -20.64% |
| MRK Stock Forecast | Merck KGaA | Buy |
17
|
157.80€ | Buy/Sell | 204.63€ | 18.19% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£14.12 | Buy/Sell | £17.30 | 14.73% |
AstraZeneca PLC Net Income Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's Net Income has grown, increasing from £1.34B to £3.29B – an increase of 146.29%. For next year, the 15 analysts predict Net Income of £11.35B, which would mean an increase of 245.32%. Over the next eight years, the pros' prediction is Net Incomeof £19.77B, which would mean a eight-year growth forecast of 501.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$237.28 | Buy/Sell | $301.27 | 22.22% |
| MMM Stock Forecast | 3M Co | Hold |
10
|
$98.51 | Buy/Sell | $110.96 | 8.62% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.06k | Buy/Sell | ¥0.00 | 25.74% |
AstraZeneca PLC EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBITDA has grown, increasing from £5.65B to £13.90B – a growth of 146.06%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBITDA of £15.34B – an increase of 10.39%. Over the next eight years, experts anticipate that AstraZeneca PLC's EBITDA will grow at a rate of 61.73%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Hold |
11
|
42.71€ | Buy/Sell | 48.98€ | 10.04% |
| LONN Stock Forecast | Lonza Group | Outperform |
16
|
CHF351.70 | Buy/Sell | CHF756.46 | 45.44% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
18
|
¥4.94k | Buy/Sell | ¥0.00 | 3.24% |
AstraZeneca PLC EBIT Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBIT has grown by 186.72%, from £3.13B to £8.96B. For the next year, analysts are expecting EBIT to reach £14.95B – an increase of 66.79%. Over the next eight years, experts predict that EBIT will grow by 194.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
30.56€ | Buy/Sell | 55.86€ | 60.34% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$227.41 | Buy/Sell | $322.44 | 36.76% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$45.50 | Buy/Sell | $59.82 | 30.77% |
AstraZeneca PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EPS has grown in the last three years, jumping from £3.50 to £6.66 – an increase of 90.29%. In the next year, analysts predict that EPS will reach £7.30 – an increase of 9.61%. For the next eight years, the forecast is for EPS to grow by 94.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$78.18 | Buy/Sell | $182.39 | 63.09% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$98.30 | Buy/Sell | $201.43 | 7.79% |
| BGNE Stock Forecast | BeiGene | Buy |
6
|
$184.84 | Buy/Sell | $0.00 | 55.27% |
.jpg)